Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Malluche, H. H.
Right arrow Articles by Mawad, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malluche, H. H.
Right arrow Articles by Mawad, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 1170-1175
© 2002 European Renal Association-European Dialysis and Transplant Association

Invited Comment

Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions

Hartmut H. Malluche and Hanna Mawad

University of Kentucky, Division of Nephrology, Bone and Mineral Metabolism, Lexington, KT 40536-0084, USA

Abstract

A historical look at research in hyperphosphataemia of chronic kidney disease over the last 40 years shows remarkable advances in our understanding of this abnormality and in the technology used to manage it. Phosphate binders, which have become a mainstay in the management of hyperphosphataemia, have evolved from the early use of aluminium gels to calcium salts, to novel, non-absorbed, aluminium-free, calcium-free agents such as sevelamer hydrochloride, and to magnesium-, iron-, and lanthanum-based compounds. With recent advances, clinical management of this complication of chronic renal disease is evolving from adequate care to optimal care, such that new standards in phosphorous management are being set, and various parameters of patient care are being integrated to optimize outcomes and minimize side effects. This paper provides a historical view of the clinical management of hyperphosphataemia, and looks to advances in treatment that are changing the course of renal bone disease management.

Keywords: aluminium; hyperphosphataemia; lanthanum; magnesium; renal bone disease; sevelamer hydrochloride

Notes

Correspondence and offprint requests to: Prof. Dr Hartmut H. Malluche, University of Kentucky, Division of Nephrology, Bone and Mineral Metabolism, 800 Rose Street, Room MN 564, Lexington, KY 40536-0084, USA. Email: hhmall{at}uky.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
C. Sullivan, S. S. Sayre, J. B. Leon, R. Machekano, T. E. Love, D. Porter, M. Marbury, and A. R. Sehgal
Effect of Food Additives on Hyperphosphatemia Among Patients With End-stage Renal Disease: A Randomized Controlled Trial
JAMA, February 11, 2009; 301(6): 629 - 635.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. J. Schucker and K. E. Ward
Hyperphosphatemia and phosphate binders
Am. J. Health Syst. Pharm., November 15, 2005; 62(22): 2355 - 2361.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Amato and S. Aterini
Management of hyperphosphataemia in chronic renal disease: lessons from the past and future directions
Nephrol. Dial. Transplant., April 1, 2003; 18(4): 848 - 848.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H. Malluche
Reply
Nephrol. Dial. Transplant., April 1, 2003; 18(4): 848 - 849.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.